Alexion Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) PT Raised to $221 at Brean Capital Amid 'Strong' Q2
July 31, 2015 7:58 AM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $221.00 (from $213.00) following "strong" Q2 results despite FX headwinds.
Aschoff commented, "Alexion reported 2Q15 Soliris revenue of $636 million, beating consensus of $630 million despite strong FX headwinds. Diluted non-GAAP EPS of $1.44 beat consensus of $1.37. Revenue guidance for 2015 increased from the previous range of $2.55-2.6 billion to $2.6-2.62 billion, including a 6%... More
Alexion Pharma (ALXN) Tops Q2 EPS by 5c; Updates FY15 Outlook
July 30, 2015 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.44, $0.05 better than the analyst estimate of $1.39. Revenue for the quarter came in at $636 million versus the consensus estimate of $628.03 million.
Alexion Pharma sees FY2015 EPS of $4.70 - $4.80, versus prior guidance of $5.60 - $5.80 and the consensus of... More
